Equities

LSL Pharma Group Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LSL:CVE

LSL Pharma Group Inc

Actions
  • Price (CAD)0.52
  • Today's Change0.00 / 0.00%
  • Shares traded24.00k
  • 1 Year change+42.47%
  • Beta--
Data delayed at least 15 minutes, as of Feb 09 2026 17:49 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. The Company’s segments include CMO activities and Integrated Eye-care pharmaceutical company. Its contract manufacturing operations include LSL Laboratory, Inc., Dermolab Pharma Ltd., Virage Sante Inc., and Laboratoire Du-Var Inc. LSL Laboratory, Inc. is engaged in the manufacturing of natural health products in solid dosage forms. Dermolab Pharma Ltd. manufactures liquid and semi-solid pharmaceutical, natural health and cosmetic products. Steri-Med Pharma Inc., the Company’s sterile eye-care manufacturing operation, specializes in the in-licensing or development/manufacturing and commercialization of sterile ophthalmic pharmaceuticals for Canada, United States and other international markets.

  • Revenue in CAD (TTM)26.80m
  • Net income in CAD2.78m
  • Incorporated2010
  • Employees--
  • Location
    LSL Pharma Group Inc540, rue d'Avaugour, Office 1800BOUCHERVILLE J4B 0G6CanadaCAN
  • Phone+1 (450) 681-7744
  • Fax+1 (450) 681-8400
  • Websitehttps://www.groupelslpharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LSL:CVE since
announced
Transaction
value
Juno OTC IncDeal completed17 Dec 202517 Dec 2025Deal completed48.57%3.58m
Laboratoire Du-Var IncDeal completed17 Nov 202517 Nov 2025Deal completed48.57%2.28m
Data delayed at least 15 minutes, as of Feb 09 2026 17:49 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Decibel Cannabis Company Inc109.31m12.32m51.46m--3.410.81662.650.47080.02640.0250.1980.11020.7952.156.51--8.96-0.040113.94-0.059521.9820.0311.27-0.06880.6086-5.570.4186---12.8971.51810.61---4.74--
Arch Biopartners Inc275.95k-1.55m52.39m--------189.87-0.0237-0.02370.0042-0.05870.5306--0.7616---298.56-195.50---------562.69-123.23---3.99-----87.0032.3760.39------
LSL Pharma Group Inc26.80m2.78m65.30m--21.662.4812.972.440.0240.0240.23070.20940.54621.985.78--5.65--7.29--29.73--10.35--0.53660.65210.5325--76.98--139.15------
Eastwood Bio-Medical Canada Inc594.57k-411.84k68.89m--------115.86-0.006-0.0060.0086-0.02252.17--26.00---150.26-71.29----63.9156.40-69.27-57.09---31.24-----19.11-11.5016.60------
Medexus Pharmaceuticals Inc141.10m516.41k91.55m91.00125.161.307.170.64890.02280.02284.712.190.70621.358.301,550,548.000.2585-3.710.4872-6.2253.0152.710.366-5.740.37631.240.2867---4.1814.311,150.00--24.90--
Data as of Feb 09 2026. Currency figures normalised to LSL Pharma Group Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.